Mikael Ryden

Title: Innovations of Mikael Ryden

Introduction

Mikael Ryden is a notable inventor based in Hagersten, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of novel serine threonine kinase receptors. With a total of 4 patents to his name, Ryden's work has implications for diagnosing and treating neurodegenerative diseases.

Latest Patents

Ryden's latest patents include groundbreaking inventions related to ALK-7, a novel serine threonine kinase receptor. The first patent focuses on nucleic acid molecules coding for ALK-7, as well as ALK-7 polypeptides and recombinant nucleic acid molecules. It also covers antibodies with specific binding affinity to ALK-7, hybridomas containing these antibodies, and nucleic acid probes for detecting ALK-7 nucleic acid. Furthermore, the invention outlines methods for detecting ALK-7 in samples and kits containing the necessary probes or antibodies. The second patent reiterates these innovations and emphasizes the therapeutic uses of ALK-7, including ligands, agonists, and antagonists of the receptor.

Career Highlights

Throughout his career, Mikael Ryden has focused on advancing the understanding of serine threonine kinase receptors. His research has led to significant advancements in the field, particularly in the context of neurodegenerative diseases. Ryden's work is characterized by a commitment to innovation and a desire to improve diagnostic and therapeutic methods.

Collaborations

Mikael Ryden has collaborated with esteemed colleagues such as Carlos F Ibanez and Henrik Jornvall. These partnerships have further enriched his research and contributed to the success of his inventions.

Conclusion

Mikael Ryden's contributions to biotechnology, particularly through his patents related to ALK-7, highlight his role as a significant inventor in the field. His work not only advances scientific knowledge but also holds promise for future therapeutic applications.